Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Bimekizumab in Ankylosing Spondylitis
2017-001002-15Phase 2Completed
- Sponsor
- UCB
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bimekizumab in ankylosing spondylitis (AS), sponsored by UCB. Primary endpoint: Incidence of Treatment-Emergent Adverse Events (TEAEs) during the study. Started Aug 2017; status: completed.
02
Drugs
bimekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2017-001002-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001002-15.